DOCSLIB.ORG

Micro-RNA Levels Higher in Aggressive Melanomas

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Micro-RNA Levels Higher in Aggressive Melanomas September 2008 • www.skinandallergynews.com Cutaneous Oncology 29 Micro-RNA Levels Higher in Aggressive Melanomas BY SHARON WORCESTER A false-positive diagnosis could lead to positive patients, compared with expres- tools in melanoma are ongoing, Dr. Southeast Bureau unnecessary treatment; a false-negative sion in benign nevi (mean 6.5-fold in- Lesinski said. diagnosis could lead to undertreatment crease), than in node-negative patients, During a discussion of Dr. Lesinski’s C HICAGO — Micro-RNA-21 and mi- and increased risk of melanoma devel- compared with expression in benign nevi findings and those from other melanoma cro-RNA-155 are expressed at significant- opment. (1.3-fold increase). biomarker studies, Elizabeth Grimm, ly higher levels in primary malignant In this study, expression of micro-RNA- “Surprisingly, we didn’t find the same re- Ph.D., said they are part of a “fabulous set melanoma tumor samples than in samples 21 and micro-RNA-155 was analyzed in in- lationship for micro-RNA-155; the data of new data.” from benign nevi—and in indeterminate determinate lesions with more than one were highly variable [for micro-RNA-155] Dr. Lesinski’s findings regarding inde- melanocytic lesions with an aggressive mitosis per 10x high-power field. regardless of whether the patients were terminate lesions are particularly impor- histological phenotype, according to data When they were node negative or tant given the therapeutic dilemma they presented at the American Society of compared with those ‘Micro-RNA-21, at least, node positive,” said pose, she said. Clinical Oncology annual meeting. with less than one Dr. Lesinski, who re- She expressed concern, however, about Samples from eight dermal nevi, 28 mitosis per 10x high- may in fact be a relevant ported he has no dis- difficulty in determining whether micro- malignant melanomas, and 49 pathologi- power field, there marker that can be used to closures relevant to RNA expression is increased in cally indeterminate melanocytic lesions was significantly the data he present- melanomas, compared with indetermi- were evaluated using real-time poly- higher expression of complement the traditional ed. nate lesions. Differences were marked be- merase chain reaction. Investigators found micro-RNA-21 (P = histological analyses used These data are tween melanoma and benign nevi, but a mean 7.6-fold increase in micro-RNA-21 .0005) and micro- “very preliminary,” based on her review of the data, it appears expression (P = .0001) and a mean 13.3- RNA-155 (P = .04). to diagnose these lesions.’ he added, noting that there was little difference in expression be- fold increase (P = .0001) in micro-RNA- Melanocytic le- the sample size for tween melanoma and indeterminate le- 155 expression, compared with the benign sions that were greater than 1 mm in this portion of the study is being expand- sions, Dr. Grimm said, adding that re- nevus samples, reported Gregory B. depth, compared with thinner lesions, ed to include at least 50 patients to make search regarding other micro-RNAs Lesinski, Ph.D., of Ohio State University, also had significantly higher levels of mi- a more accurate statistical determination should continue. Columbus. cro-RNA-155 (P = .01), suggesting these about the expression of these micro- She also noted that she is curious about Another potential biomarker—micro- might have more malignant potential; RNAs. whether there is a micro-RNA signature RNA-21b—showed a trend toward in- micro-RNA-21 was higher in the thicker “Nonetheless, these data are very entic- that adds value to the current staging sys- creased expression, but the difference did lesions as well, but the difference did not ing to us, and they suggest that micro- tem and markers commonly used, and not reach statistical significance in this reach statistical significance, Dr. Lesinski RNA-21, at least, may in fact be a relevant whether micro-RNAs can be used inde- small sample size (P = .07). However, mi- said. marker that can be used to complement pendently of common diagnostic markers cro-RNA-21b remains of interest, Dr. In a subset of 13 patients with indeter- the traditional histological analyses used to used by pathologists, such as MAGE, Lesinski noted. minate lesions whose lesions were con- diagnose these lesions,” he said. MART, and S100B. Micro-RNA-21 and micro-RNA-155 also sidered suspicious enough that the pa- The expression of micro-RNAs—a While many questions remain, she ap- appear to be expressed at higher levels in tients were sent for sentinel node biopsy, group of more than 200 recently identified plauded the research effort, noting that certain indeterminate melanocytic le- micro-RNA-21 and micro-RNA-155 ex- noncoding molecules considered to be a there are valid markers in other tumor sions. Indeterminate lesions, including pression were compared with expression new class of oncogenes—is altered in types; thus, the “noble” efforts to identify deep penetrating nevi, dysplastic nevi, in benign nevi—in both those that proved many types of tumors. molecular markers for melanoma are and Spitz nevi, pose a particular chal- node positive and those that proved node This study is among the first to explore worthwhile. “We’re not just dreaming— lenge in that diagnosis and determination negative. this expression in melanoma. Studies to we will have them for melanoma some of the appropriate course of action are Micro-RNA expression was signifi- further assess the potential value of mi- day,” said Dr. Grimm of M.D. Anderson uncertain. cantly higher in the lesions from node- cro-RNAs as diagnostic and prognostic Cancer Center, Houston. ■ Gene Loss May Explain Gender Differences in Melanoma BY SHARON WORCESTER vival (P = .015), reported Dr. Spatz of Institut Gustave cess risk of death of 1.87, compared with women with Southeast Bureau Roussy in Villejuif, France. melanoma. Further investigation to identify any particular gene or “We can conclude that there is a very specific pattern C HICAGO — A specific pattern of X and Y chromo- genes that fulfilled the criteria of being located on the X of X and Y chromosome losses associated with melanoma some losses—and in particular the loss of an important chromosome in women and escaping inactivation of X progression … and that PPP2R3B appears from this tumor-suppression gene—was shown in a recent study to chromosome, as well as being located on the Y chromo- study to be a very important tumor suppression gene be associated with melanoma progression. some in men, showed that only the PPP2R3B gene, also whose loss is associated with tumor progression. This “very new and very unexpected finding” could know as PR48, did so. “Does this explain the gender effect? Maybe if indeed help explain gender differences that are seen in The normalized expression of the gene, which is lo- we show that there is a differential frequency of inacti- melanoma, such as the increased cated on Xp22 in women and on Yp11 vated X chromosome in females, as compared with Y risk of death in men with mel- ‘PPP2R3B appears from in men was found to be associated chromosome—but this is still an open question,” Dr. anoma, compared with women with with distant metastasis-free survival Spatz said. melanoma, Dr. Alan Spatz said at the this study to be a very at a “totally unexpected level of sig- In a discussion of the findings, Elizabeth Grimm, American Society of Clinical On- important tumor nificance,” (P = .0007), after adjusting Ph.D., a professor at the University of Texas M.D. An- cology annual meeting, where he for clinical and pathologic prognostic derson Cancer Center, Houston, called these and other presented the findings. suppression gene whose variables, including gender, age, ul- emerging data a “snapshot of finest biomarker work in Frozen sections from 48 mel- loss is associated with ceration, and thickness, Dr. Spatz said. melanoma at this time.” Dr. Spatz’s work is particularly anomas—taken from 32 women and tumor progression.’ PR48 is a lesser-known subunit of a provocative, she said. 16 men with a median follow-up of well-known and very important gene She asked, however, how—given the findings—one 4 years—were analyzed as part of a (serine/threonine protein phosphatase would explain that the incidence of melanoma in young European Organisation for Research and Treatment of 2A) which he described as “kind of a gatekeeper in cell women is higher than that in young men. The increased Cancer (EORTC) study. Analyses of DNA and mRNA biology,” he said. incidence in men only begins to become evident around were conducted; the end point was distant metastasis- PR48 mediates the dephosphorylation of CDC6 by age 50 years, she noted, questioning whether other free survival. phosphatase 2A and controls initiation of DNA repli- lifestyle parameters are in play. A significant correlation was found between DNA cation in human cancer cells, especially melanoma, he “Just food for thought,” she said. copy number and mRNA level for 1,455 genes (P less than explained. Dr. Grimm also noted that it would be interesting, .05). In the women’s samples, losses in the X chromosome The findings, along with those from other ongoing should the findings be validated in the ongoing studies were significantly associated with distant metastasis-free studies that are designed to help improve understand- that Dr. Spatz mentioned, to see how they might change survival (P = .009), and the affected X chromosome was ing of PPP2R3B biology, could potentially provide bio- the course of treatment or provide prognostic infor- always the inactive X. logic clues regarding gender differences in melanoma mation, and to determine whether some form of gene In the men, losses in the Y chromosome were sig- progression and survival; the gender effect in melanoma therapy to redeliver the X and Y chromosome losses nificantly associated with distant metastasis-free sur- is strong—men have been shown to have a relative ex- could be developed.
Load more

Recommended publications
  • 13 Effect of Hypoxia on Expression of the PP2A System in Primary Human Cardiovascular Cells: Post-Translation Modification and Involvement of Hif1α
    Abstracts 13 EFFECT OF HYPOXIA ON EXPRESSION OF THE PP2A activity was decreased (p<0.05) in both HASMC and HCF-av SYSTEM IN PRIMARY HUMAN CARDIOVASCULAR CELLS: following hypoxia (24 hour) while no effect was observed in POST-TRANSLATION MODIFICATION AND HAEC. Protein expression of the catalytic subunit of PP2A INVOLVEMENT OF HIF1a only decreased (p<0.05) after exposure to hypoxia for 72 hour in all cell lines. In HASMC, 24 hour hypoxia I Elgenaidi, JP Spiers. Department of Pharmacology and Therapeutics, Trinity College, increased demethylated PP2CA and phosphorylated PP2CA Dublin, Ireland abundance (p<0.05) and increased PME abundance (p<0.05). DMOG (100 mM) decreased both mRNA and protein Activity 10.1136/heartjnl-2017-311433.13 of PPP2CA. In conclusion, hypoxia suppresses the expression of PP2A Dysregulation of protein phosphorylation has been linked to in cardiac endothelial, smooth muscle and fibroblast with mechanical dysfunction and arrhythmias in a host of highly kinetics that are both cell and time dependent. In HASMC, 1 prevalent cardiovascular disorders. Little is known about the hypoxia cause post-translational modification of PP2A attenuat- effect of hypoxia on PP2A expression and regulation in the ing its activity. Furthermore, prolyl-hydroxylase inhibition cardiovascular system. The aim of this work was to: (i) deter- decreased PP2CA expression suggesting that HIF-1a may play mine the expression profile of PP2A in different cardiovascu- a role in modulating the PP2A system during hypoxia in the lar cells (HAEC, HASMC and HCF-av), investigate how this cardiovascular system. changes under hypoxia and following hydroxylase inhibition, (ii) study post-translational regulation of PP2A in HASMC REFERENCE under hypoxic conditions.
    [Show full text]
  • Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
    Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
    [Show full text]
  • Identification of the First PAR1 Deletion Encompassing Upstream SHOX Enhancers in a Family with Idiopathic Short Stature
    European Journal of Human Genetics (2012) 20, 125–127 & 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12 www.nature.com/ejhg SHORT REPORT Identification of the first PAR1 deletion encompassing upstream SHOX enhancers in a family with idiopathic short stature Sara Benito-Sanz1,2, Miriam Aza-Carmona1,2, Amaya Rodrı´guez-Estevez3, Ixaso Rica-Etxebarria2,3, Ricardo Gracia4,A´ ngel Campos-Barros1,2 and Karen E Heath*,1,2 Short stature homeobox-containing gene, MIM 312865 (SHOX) is located within the pseudoautosomal region 1 (PAR1) of the sex chromosomes. Mutations in SHOX or its downstream transcriptional regulatory elements represent the underlying molecular defect in B60% of Le´ri-Weill dyschondrosteosis (LWD) and B5–15% of idiopathic short stature (ISS) patients. Recently, three novel enhancer elements have been identified upstream of SHOX but to date, no PAR1 deletions upstream of SHOX have been observed that only encompass these enhancers in LWD or ISS patients. We set out to search for genetic alterations of the upstream SHOX regulatory elements in 63 LWD and 100 ISS patients with no known alteration in SHOX or the downstream enhancer regions using a specifically designed MLPA assay, which covers the PAR1 upstream of SHOX. An upstream SHOX deletion was identified in an ISS proband and her affected father. The deletion was confirmed and delimited by array-CGH, to extend B286 kb. The deletion included two of the upstream SHOX enhancers without affecting SHOX. The 13.3-year-old proband had proportionate short stature with normal GH and IGF-I levels. In conclusion, we have identified the first PAR1 deletion encompassing only the upstream SHOX transcription regulatory elements in a family with ISS.
    [Show full text]
  • NRF1) Coordinates Changes in the Transcriptional and Chromatin Landscape Affecting Development and Progression of Invasive Breast Cancer
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 11-7-2018 Decipher Mechanisms by which Nuclear Respiratory Factor One (NRF1) Coordinates Changes in the Transcriptional and Chromatin Landscape Affecting Development and Progression of Invasive Breast Cancer Jairo Ramos [email protected] Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Clinical Epidemiology Commons Recommended Citation Ramos, Jairo, "Decipher Mechanisms by which Nuclear Respiratory Factor One (NRF1) Coordinates Changes in the Transcriptional and Chromatin Landscape Affecting Development and Progression of Invasive Breast Cancer" (2018). FIU Electronic Theses and Dissertations. 3872. https://digitalcommons.fiu.edu/etd/3872 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida DECIPHER MECHANISMS BY WHICH NUCLEAR RESPIRATORY FACTOR ONE (NRF1) COORDINATES CHANGES IN THE TRANSCRIPTIONAL AND CHROMATIN LANDSCAPE AFFECTING DEVELOPMENT AND PROGRESSION OF INVASIVE BREAST CANCER A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in PUBLIC HEALTH by Jairo Ramos 2018 To: Dean Tomás R. Guilarte Robert Stempel College of Public Health and Social Work This dissertation, Written by Jairo Ramos, and entitled Decipher Mechanisms by Which Nuclear Respiratory Factor One (NRF1) Coordinates Changes in the Transcriptional and Chromatin Landscape Affecting Development and Progression of Invasive Breast Cancer, having been approved in respect to style and intellectual content, is referred to you for judgment.
    [Show full text]
  • The Human Gene Connectome As a Map of Short Cuts for Morbid Allele Discovery
    The human gene connectome as a map of short cuts for morbid allele discovery Yuval Itana,1, Shen-Ying Zhanga,b, Guillaume Vogta,b, Avinash Abhyankara, Melina Hermana, Patrick Nitschkec, Dror Friedd, Lluis Quintana-Murcie, Laurent Abela,b, and Jean-Laurent Casanovaa,b,f aSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065; bLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U980, Necker Medical School, 75015 Paris, France; cPlateforme Bioinformatique, Université Paris Descartes, 75116 Paris, France; dDepartment of Computer Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; eUnit of Human Evolutionary Genetics, Centre National de la Recherche Scientifique, Unité de Recherche Associée 3012, Institut Pasteur, F-75015 Paris, France; and fPediatric Immunology-Hematology Unit, Necker Hospital for Sick Children, 75015 Paris, France Edited* by Bruce Beutler, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 15, 2013 (received for review October 19, 2012) High-throughput genomic data reveal thousands of gene variants to detect a single mutated gene, with the other polymorphic genes per patient, and it is often difficult to determine which of these being of less interest. This goes some way to explaining why, variants underlies disease in a given individual. However, at the despite the abundance of NGS data, the discovery of disease- population level, there may be some degree of phenotypic homo- causing alleles from such data remains somewhat limited. geneity, with alterations of specific physiological pathways under- We developed the human gene connectome (HGC) to over- come this problem.
    [Show full text]
  • Anti-PPP2R3B Antibody (ARG40237)
    Product datasheet [email protected] ARG40237 Package: 100 μl anti-PPP2R3B antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes PPP2R3B Tested Reactivity Hu Tested Application WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name PPP2R3B Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 356-575 of Human PPP2R3B (NP_037371.2). Conjugation Un-conjugated Alternate Names PPP2R3L; PR48; PPP2R3LY; Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit beta; Protein phosphatase 2A 48 kDa regulatory subunit; NYREN8; PP2A subunit B isoform PR48 Application Instructions Application table Application Dilution WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control SKOV3 and SW620 Calculated Mw 65 kDa Observed Size ~ 70 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Gene Symbol PPP2R3B Gene Full Name protein phosphatase 2, regulatory subunit B'', beta Background Protein phosphatase 2 (formerly named type 2A) is one of the four major Ser/Thr phosphatases and is implicated in the negative control of cell growth and division.
    [Show full text]
  • Protein Family Members. the GENE.FAMILY
    Table 3: Protein family members. The GENE.FAMILY col- umn shows the gene family name defined either by HGNC (superscript `H', http://www.genenames.org/cgi-bin/family_ search) or curated manually by us from Entrez IDs in the NCBI database (superscript `C' for `Custom') that we have identified as corresonding for each ENTITY.ID. The members of each gene fam- ily that are in at least one of our synaptic proteome datasets are shown in IN.SYNAPSE, whereas those not found in any datasets are in the column OUT.SYNAPSE. In some cases the intersection of two HGNC gene families are needed to specify the membership of our protein family; this is indicated by concatenation of the names with an ampersand. ENTITY.ID GENE.FAMILY IN.SYNAPSE OUT.SYNAPSE AC Adenylate cyclasesH ADCY1, ADCY2, ADCY10, ADCY4, ADCY3, ADCY5, ADCY7 ADCY6, ADCY8, ADCY9 actin ActinsH ACTA1, ACTA2, ACTB, ACTC1, ACTG1, ACTG2 ACTN ActininsH ACTN1, ACTN2, ACTN3, ACTN4 AKAP A-kinase anchoring ACBD3, AKAP1, AKAP11, AKAP14, proteinsH AKAP10, AKAP12, AKAP17A, AKAP17BP, AKAP13, AKAP2, AKAP3, AKAP4, AKAP5, AKAP6, AKAP8, CBFA2T3, AKAP7, AKAP9, RAB32 ARFGEF2, CMYA5, EZR, MAP2, MYO7A, MYRIP, NBEA, NF2, SPHKAP, SYNM, WASF1 CaM Endogenous ligands & CALM1, CALM2, EF-hand domain CALM3 containingH CaMKK calcium/calmodulin- CAMKK1, CAMKK2 dependent protein kinase kinaseC CB CalbindinC CALB1, CALB2 CK1 Casein kinase 1C CSNK1A1, CSNK1D, CSNK1E, CSNK1G1, CSNK1G2, CSNK1G3 CRHR Corticotropin releasing CRHR1, CRHR2 hormone receptorsH DAGL Diacylglycerol lipaseC DAGLA, DAGLB DGK Diacylglycerol kinasesH DGKB,
    [Show full text]
  • SUPPLEMENTARY APPENDIX Exome Sequencing Reveals Heterogeneous Clonal Dynamics in Donor Cell Myeloid Neoplasms After Stem Cell Transplantation
    SUPPLEMENTARY APPENDIX Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation Julia Suárez-González, 1,2 Juan Carlos Triviño, 3 Guiomar Bautista, 4 José Antonio García-Marco, 4 Ángela Figuera, 5 Antonio Balas, 6 José Luis Vicario, 6 Francisco José Ortuño, 7 Raúl Teruel, 7 José María Álamo, 8 Diego Carbonell, 2,9 Cristina Andrés-Zayas, 1,2 Nieves Dorado, 2,9 Gabriela Rodríguez-Macías, 9 Mi Kwon, 2,9 José Luis Díez-Martín, 2,9,10 Carolina Martínez-Laperche 2,9* and Ismael Buño 1,2,9,11* on behalf of the Spanish Group for Hematopoietic Transplantation (GETH) 1Genomics Unit, Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IiSGM), Madrid; 2Gregorio Marañón Health Research Institute (IiSGM), Madrid; 3Sistemas Genómicos, Valencia; 4Department of Hematology, Puerta de Hierro General University Hospital, Madrid; 5Department of Hematology, La Princesa University Hospital, Madrid; 6Department of Histocompatibility, Madrid Blood Centre, Madrid; 7Department of Hematology and Medical Oncology Unit, IMIB-Arrixaca, Morales Meseguer General University Hospital, Murcia; 8Centro Inmunológico de Alicante - CIALAB, Alicante; 9Department of Hematology, Gregorio Marañón General University Hospital, Madrid; 10 Department of Medicine, School of Medicine, Com - plutense University of Madrid, Madrid and 11 Department of Cell Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain *CM-L and IB contributed equally as co-senior authors. Correspondence:
    [Show full text]
  • Protein Phosphatase 2A Regulatory Subunits and Cancer
    Biochimica et Biophysica Acta 1795 (2009) 1–15 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbacan Review Protein phosphatase 2A regulatory subunits and cancer Pieter J.A. Eichhorn 1, Menno P. Creyghton 2, René Bernards ⁎ Division of Molecular Carcinogenesis, Center for Cancer Genomics and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands article info abstract Article history: The serine/threonine protein phosphatase (PP2A) is a trimeric holoenzyme that plays an integral role in the Received 7 April 2008 regulation of a number of major signaling pathways whose deregulation can contribute to cancer. The Received in revised form 20 May 2008 specificity and activity of PP2A are highly regulated through the interaction of a family of regulatory B Accepted 21 May 2008 subunits with the substrates. Accumulating evidence indicates that PP2A acts as a tumor suppressor. In this Available online 3 June 2008 review we summarize the known effects of specific PP2A holoenzymes and their roles in cancer relevant pathways. In particular we highlight PP2A function in the regulation of MAPK and Wnt signaling. Keywords: Protein phosphatase 2A © 2008 Elsevier B.V. All rights reserved. Signal transduction Cancer Contents 1. Introduction ............................................................... 1 2. PP2A structure and function ....................................................... 2 2.1. The catalytic subunit (PP2Ac).................................................... 2 2.2. The structural subunit (PR65) ................................................... 3 2.3. The regulatory B subunits ..................................................... 3 2.3.1. The B/PR55 family of B subunits .............................................. 3 2.3.2. The B′/PR61 family of β subunits ............................................. 4 2.3.3. The B″/PR72 family of β subunits ............................................
    [Show full text]
  • Accurate Mutation Annotation and Functional Prediction Enhance the Applicability of -Omics Data in Precision Medicine
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 5-2016 Accurate mutation annotation and functional prediction enhance the applicability of -omics data in precision medicine Tenghui Chen Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Computational Biology Commons, Genomics Commons, and the Medicine and Health Sciences Commons Recommended Citation Chen, Tenghui, "Accurate mutation annotation and functional prediction enhance the applicability of -omics data in precision medicine" (2016). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 666. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/666 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. ACCURATE MUTATION ANNOTATION AND FUNCTIONAL PREDICTION
    [Show full text]
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards
    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein
    [Show full text]
  • Open Full Page
    Published OnlineFirst December 22, 2016; DOI: 10.1158/2159-8290.CD-RW2016-239 RESEARCH WATCH Melanoma Major finding: PPP2R3B dosage is Mechanism: PPP2R3B stabilizes the Impact: As a sex-linked tumor suppres- associated with sex chromosome CD6–CDT1 interaction to delay DNA rep- sor, PPP2R3B may explain the gender status and outcome in melanoma. lication and suppress melanoma growth. differences in melanoma prognoses. PPP2R3B IS A SEX-LINKED MELANOMA TUMOR SUPPRESSOR GENE In patients with melanoma, males tend to have was associated with reduced cell growth, and overex- a poorer prognosis than females, but the biological pression of PR70 prevented 3-D colony formation. mechanisms underlying this sex difference have not Further, overexpression of PR70 reduced melanoma been elucidated. Van Kempen and colleagues hypoth- xenograft growth in vivo, suggesting a role as a tumor esized that differences in gene dosage from the sex suppressor. However, in contrast to classic tumor chromosomes might contribute to the sex differ- suppressor genes, PPP2R3B is not frequently mutated ences in melanoma. Analysis of primary melanomas in melanoma. Mechanistically, PR70 overexpression revealed that loss of the inactive X chromosome disrupted the interaction between CDC6 and CDT1, (Xi) is associated with a poorer distant metastasis-free survival. which is crucial in initiating the fi ring of DNA replication ori- Moreover, men with Y chromosome loss also had a poorer prog- gins. Thus, PR70 overexpression delayed the progression from nosis, prompting the investigation of the pseudoautosomal G1 to S phase by limiting replication origin fi ring. Altogether, region (PAR), which is present on both the X and Y chromo- these fi ndings identify PPP2R3B as a sex-linked tumor suppres- somes and commonly escapes inactivation on Xi.
    [Show full text]